PROJ ECT SU M MARY (See Instructions): The Hollings Cancer Center (HCC) is directed by Andrew S. Kraft, MD with the assistance of a senior leadership team, and together they represent the strong functional nexus of this matrix-based Center. The team is comprised of eight associate directors, each of whom has outstanding expertise in their area of responsibility. They are: Anthony J. Alberg, PhD, MPH, Associate Director of Cancer Control;Marvella E. Ford, PhD, Associate Director of Cancer Disparities;Anita L. Harrison, MPA, Associate Director of Administration;Philip H. Howe, PhD, Associate Director of Basic Sciences;Michael B. Lilly, MD, Associate Director of Translational Research;Steven A. Rosenzweig, PhD, Associate Director of Shared Resources;Melanie B. Thomas, MD, Associate Director of Clinical Investigations;Dennis K. Watson, PhD, Associate Director of Education &Training;and Kevin F. Staveley-O'Carroll, MD, PhD, Medical Director of the HCC Clinical Service Line. The HCC senior leadership team meets once a month as a formal Executive Council, one-on-one with the Director at least monthly, and more frequently with each other and the Director in the context of various HCC board/committee meetings. They provide direct counsel and recommendations to the Director based on these interactions. All final authority for decisions on behalf of the HCC resides with the Director. Dr. Kraft has charged the senior leadership with employing consensus-building techniques as they work directly with the program leaders, shared resource directors, and various HCC boards and committees in formulating center-wide priorities, strategies, and allocation of resources. They work together as a team to ensure consistency in the mission, vision, and goals of the Center and develop synergistic interactions among the basic, translational, and clinical elements of the Center. They provide feedback on the growth of the HCC in their area of responsibility, which is particularly important given the rapid growth of the HCC, and evolving research directions at the national level. Based on this, they plan and implement proactive, integrative approaches for development of the research base, resources, and a formal strategic plan. The consistency of vision is particularly important in effectively leveraging all available resources at MUSC and at the state and national levels and engagement of the community in outreach activities.

Public Health Relevance

Support is requested for the senior leadership of the Hollings Cancer Center. This leadership is critical to ensuring the overall success of the Center in meeting its mission and goals and in the strategic planning and evaluation of all Center efforts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA138313-06
Application #
8695837
Study Section
Subcommittee G - Education (NCI)
Project Start
2009-04-01
Project End
2019-03-31
Budget Start
2014-06-20
Budget End
2015-03-31
Support Year
6
Fiscal Year
2014
Total Cost
$274,637
Indirect Cost
$90,714
Name
Medical University of South Carolina
Department
Type
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29403
Song, J H; An, N; Chatterjee, S et al. (2015) Deletion of Pim kinases elevates the cellular levels of reactive oxygen species and sensitizes to K-Ras-induced cell killing. Oncogene 34:3728-36
Zemskova, Marina Y; Song, Jin H; Cen, Bo et al. (2015) Regulation of prostate stromal fibroblasts by the PIM1 protein kinase. Cell Signal 27:135-46
Boppana, Nithin B; Kodiha, Mohamed; Stochaj, Ursula et al. (2014) Ceramide synthase inhibitor fumonisin B1 inhibits apoptotic cell death in SCC17B human head and neck squamous carcinoma cells after Pc4 photosensitization. Photochem Photobiol Sci 13:1621-7
God, Jason M; Zhao, Dan; Cameron, Christine A et al. (2014) Disruption of HLA class II antigen presentation in Burkitt lymphoma: implication of a 47,000 MW acid labile protein in CD4+ T-cell recognition. Immunology 142:492-505
Esnaola, Nestor F; Chaudhary, Uzair B; O'Brien, Paul et al. (2014) Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 88:837-44
Fuseler, John W; Robichaux, Jacqulyne P; Atiyah, Huda I et al. (2014) Morphometric and fractal dimension analysis identifies early neoplastic changes in mammary epithelium of MMTV-cNeu mice. Anticancer Res 34:1171-7
Hussey, Sophie E; Lum, Helen; Alvarez, Andrea et al. (2014) A sustained increase in plasma NEFA upregulates the Toll-like receptor network in human muscle. Diabetologia 57:582-91
Chen, Weiqin; Zhou, Hongyi; Saha, Pradip et al. (2014) Molecular mechanisms underlying fasting modulated liver insulin sensitivity and metabolism in male lipodystrophic Bscl2/Seipin-deficient mice. Endocrinology 155:4215-25
Kesarwani, Pravin; Al-Khami, Amir A; Scurti, Gina et al. (2014) Promoting thiol expression increases the durability of antitumor T-cell functions. Cancer Res 74:6036-47
He, Huacheng; Cattran, Alexander W; Nguyen, Tu et al. (2014) Triple-responsive expansile nanogel for tumor and mitochondria targeted photosensitizer delivery. Biomaterials 35:9546-53

Showing the most recent 10 out of 162 publications